---
title: "IDEXX Laboratories Inc. Stock Underperforms Tuesday When Compared To Competitors"
description: "IDEXX Laboratories Inc. (IDXX) shares fell 1.10% to $632.56 on Tuesday, marking the sixth consecutive day of losses. The stock is now 17.85% below its 52-week high of $769.98. In contrast, competitors"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274718219.md"
published_at: "2026-02-03T21:50:52.000Z"
---

# IDEXX Laboratories Inc. Stock Underperforms Tuesday When Compared To Competitors

> IDEXX Laboratories Inc. (IDXX) shares fell 1.10% to $632.56 on Tuesday, marking the sixth consecutive day of losses. The stock is now 17.85% below its 52-week high of $769.98. In contrast, competitors like Johnson & Johnson (JNJ) and Medtronic PLC (MDT) saw gains of 1.02% and 0.46%, respectively. The overall market also declined, with the S&P 500 down 0.84%. Trading volume for IDXX was 632,848, surpassing its 50-day average of 547,981.

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of IDEXX Laboratories Inc. (IDXX) slipped 1.10% to $632.56 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.84% to 6,917.81 and Dow Jones Industrial Average falling 0.34% to 49,240.99.

This was the stock's sixth consecutive day of losses.

IDEXX Laboratories Inc. closed 17.85% below its 52-week high of $769.98, which the company reached on November 26th.

The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 1.02% to $233.10, Medtronic PLC (MDT) rose 0.46% to $103.18, and Boston Scientific Corp. (BSX) fell 0.27% to $91.62.

Trading volume (632,848) eclipsed its 50-day average volume of 547,981.

Data source: Dow Jones Market Data, FactSet. Data compiled February 3, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

02-03-26 1650ET

### Related Stocks

- [XHE.US - SPDR S&P Health Equip](https://longbridge.com/en/quote/XHE.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [LABD.US - Direxion S&P Biotech Bear 3X](https://longbridge.com/en/quote/LABD.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [IHI.US - iShares US Medical Devices](https://longbridge.com/en/quote/IHI.US.md)
- [IDXX.US - IDEXX Labs](https://longbridge.com/en/quote/IDXX.US.md)
- [IDNA.US - iShares Genomics Immunology and Healthcare ETF](https://longbridge.com/en/quote/IDNA.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) 的空头头寸更新 | Monte Rosa Therapeutics, Inc.（纳斯达克代码：GLUE）在空头头寸方面经历了显著增长，截至 1 月 30 日，空头头寸增加了 38.0%，达到 7,664,016 股。这大约占公司已售空股份的 12.6%，基于平 | [Link](https://longbridge.com/en/news/276012469.md) |
| Uniting Wealth Partners LLC 收购了 5,056 股强生公司$JNJ 股票 | 联合财富伙伴公司（Uniting Wealth Partners LLC）在第三季度收购了 5,056 股强生（Johnson & Johnson，NYSE: JNJ），价值约为 938,000 美元。其他机构投资者也调整了他们的持仓，SO | [Link](https://longbridge.com/en/news/276006840.md) |
| 在分析师的积极评价和研发管线取得进展后，评估 MBX Biosciences（MBX）的估值 | MBX Biosciences (MBX) 因其肽疗法管线的进展和分析师的积极情绪而受到关注。目前股价为 38.09 美元，过去 30 天股价下跌了 6.02%，但在 90 天内上涨了 48.73%，反映出强劲的长期动能。MBX 的市净率为 | [Link](https://longbridge.com/en/news/276031364.md) |
| Biocon 计划通过推出仿制减肥药来推动收入增长 | Biocon 计划通过全球推出包括诺和诺德的 Wegovy 和利拉鲁肽在内的仿制减肥药，实现高双位数的收入增长。该公司计划在下一个财年在美国推出仿制利拉鲁肽，并在加拿大推出 Wegovy，同时由于激烈的价格竞争和监管障碍，对进入印度市场持谨 | [Link](https://longbridge.com/en/news/276028392.md) |
| X4 Pharmaceuticals 详细介绍了 Mavorixafor 的三期推进计划、成本削减措施以及慢性中性粒细胞减少症的市场计划 | X4 Pharmaceuticals 正在专注于推进 mavorixafor 用于慢性中性粒细胞减少症，旨在确立其在罕见血液疾病治疗领域的地位。执行主席 Adam Craig 在 Guggenheim 的一次交流中讨论了运营变更、成本削减和 | [Link](https://longbridge.com/en/news/276041918.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.